Deborah Lindquist

5.4k total citations · 1 hit paper
22 papers, 3.0k citations indexed

About

Deborah Lindquist is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Deborah Lindquist has authored 22 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Deborah Lindquist's work include HER2/EGFR in Cancer Research (14 papers), Cancer Treatment and Pharmacology (11 papers) and Advanced Breast Cancer Therapies (7 papers). Deborah Lindquist is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Cancer Treatment and Pharmacology (11 papers) and Advanced Breast Cancer Therapies (7 papers). Deborah Lindquist collaborates with scholars based in United States, United Kingdom and France. Deborah Lindquist's co-authors include David Cameron, Charles E. Geyer, Steven Stein, Mario Campone, Agnieszka Jagiełło-Gruszfeld, Cristina Oliva, John Crown, Stephen Chan, Stephen D. Rubin and Bella Kaufman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Deborah Lindquist

22 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

2006 2.5k citations Charles E. Geyer, Deborah Lindquist et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deborah Lindquist United States	10	2.5k	938	812	655	648	22	3.0k
Steven Stein United States	11	3.0k 1.2×	1.2k 1.3×	1.0k 1.2×	859 1.3×	762 1.2×	21	3.7k
Zefei Jiang China	30	2.5k 1.0×	1.2k 1.3×	744 0.9×	1.1k 1.7×	915 1.4×	198	3.8k
Michael W. Lu United States	14	2.9k 1.1×	1.0k 1.1×	1.6k 2.0×	675 1.0×	530 0.8×	18	3.7k
Stephen D. Rubin United States	13	2.6k 1.0×	1.3k 1.4×	811 1.0×	1.1k 1.7×	673 1.0×	17	4.0k
Alexey Manikhas Russia	23	3.1k 1.2×	1.4k 1.5×	763 0.9×	880 1.3×	1.4k 2.1×	89	3.9k
Binghe Xu China	26	2.4k 0.9×	1.0k 1.1×	482 0.6×	666 1.0×	1000 1.5×	149	3.1k
Alvaro Moreno‐Aspitia United States	26	1.9k 0.7×	664 0.7×	481 0.6×	632 1.0×	781 1.2×	105	2.7k
Ellie Guardino United States	17	3.9k 1.6×	1.3k 1.4×	2.2k 2.7×	860 1.3×	619 1.0×	30	4.7k
Nancy T. Sklarin United States	17	1.6k 0.6×	397 0.4×	784 1.0×	783 1.2×	418 0.6×	36	2.3k
José Luiz Pedrini Brazil	16	4.2k 1.6×	1.5k 1.6×	1.6k 1.9×	699 1.1×	1.8k 2.8×	28	5.0k

Countries citing papers authored by Deborah Lindquist

Since Specialization

Citations

This map shows the geographic impact of Deborah Lindquist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Lindquist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Lindquist more than expected).

Fields of papers citing papers by Deborah Lindquist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Lindquist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Lindquist. The network helps show where Deborah Lindquist may publish in the future.

Co-authorship network of co-authors of Deborah Lindquist

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Lindquist. A scholar is included among the top collaborators of Deborah Lindquist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Lindquist. Deborah Lindquist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paul, Devchand, Svetislava J. Vukelja, Frankie A. Holmes, et al.. (2019). Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients. npj Breast Cancer. 5(1). 11 indexed citations

Lindquist, Deborah, et al.. (2018). Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease. Case Reports in Oncology. 11(3). 855–860. 4 indexed citations

Honce, Justin M., et al.. (2018). Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clinical Lung Cancer. 20(2). e133–e136. 6 indexed citations

O’Shaughnessy, Joyce, Katarína Petráková, Gabe S. Sonke, et al.. (2017). Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment. 168(1). 127–134. 87 indexed citations

Strasser‐Weippl, Kathrin, Nora Horick, Ian E. Smith, et al.. (2016). Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer. 56. 85–92. 4 indexed citations

Strasser‐Weippl, Kathrin, Nora Horick, Ian E. Smith, et al.. (2015). Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research. 17(1). 56–56. 26 indexed citations

Paul, Devchand, Scot Sedlacek, Anne Favret, et al.. (2013). Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. The Lancet Oncology. 14(11). 1121–1128. 92 indexed citations

Vahdat, Linda T., Agustin A. García, Charles L. Vogel, et al.. (2013). Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Research and Treatment. 140(2). 341–351. 46 indexed citations

O’Shaughnessy, Joyce, David Loesch, Devchand Paul, et al.. (2013). ER as a predictor of early breast cancer (EBC) outcomes in patients.. Journal of Clinical Oncology. 31(15_suppl). 590–590. 1 indexed citations

10.

Goss, Paul E., Ian E. Smith, Joyce O’Shaughnessy, et al.. (2012). Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. The Lancet Oncology. 14(1). 88–96. 100 indexed citations

11.

George, Timothy, Stefan Krüger, Anne Favret, et al.. (2012). Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. Annals of Oncology. 23(10). 2599–2605. 6 indexed citations

12.

Vahdat, Linda T., Agustin A. García, Charles L. Vogel, et al.. (2012). Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study.. Journal of Clinical Oncology. 30(27_suppl). 121–121. 1 indexed citations

13.

O’Shaughnessy, Joyce, John Pippen, Devchand Paul, et al.. (2012). Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.. Journal of Clinical Oncology. 30(15_suppl). 547–547. 3 indexed citations

14.

Pippen, John, Devchand Paul, Christopher Stokoe, et al.. (2011). Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.. Journal of Clinical Oncology. 29(15_suppl). 500–500. 9 indexed citations

15.

Vahdat, Linda T., P. Gopalakrishna, Charles L. Vogel, et al.. (2011). P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.. Cancer Research. 71(24_Supplement). P5–19. 1 indexed citations

16.

Loesch, David, F. Anthony Greco, Neil Senzer, et al.. (2010). Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer. Journal of Clinical Oncology. 28(18). 2958–2965. 17 indexed citations

17.

O’Shaughnessy, Joyce, Christopher Stokoe, John Pippen, et al.. (2010). Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer. Cancer Research. 70(24_Supplement). S4–2. 29 indexed citations

18.

Geyer, Charles E., Deborah Lindquist, Stephen Chan, et al.. (2006). Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 355(26). 2733–2743. 2498 indexed citations breakdown →

19.

Sandbach, John F., et al.. (2006). Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age ≤65 and performance status 2. Lung Cancer. 52(3). 313–317. 2 indexed citations

20.

Neubauer, Marcus A., David Garfield, Robert N. Raju, et al.. (2004). Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer. 47(1). 121–127. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact